It remains an investigational drug studied primarily for obesity and type 2 diabetes
Hypoglycemia (RR 353, 95% CI 199 to 627) and total adverse reactions (RR 114, 95% CI 110 to 119) occurred more frequently in the daily group than that in the weekly group ( Table S19 )
The rise of telemedicine and digital health services is enhancing reach, especially in tier-2 and tier-3 cities, allowing companies to tap into previously underserved populations
we provide continuous support, monitoring your progress and making adjustments as needed
It is FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (obesity, 2023)
Providers like Klarity Health can transition you back to insurance billing if your coverage situation changes, ensuring continuity of care throughout the process